JUBILANT PHARMOVA
|
|
BOM : 530019     NSE : JUBLPHARMA     | |
LT :  
    Long Term Analysis
Fundamentals : Good
Valuation : Good [Stock is Cheap] Debt : High |
Updated: |
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Neutral
Price Momentum : Downward Pledged Shares : NA |
Jun 29,2022 |
Price(EOD): ₹ 346.30
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
MCap: ₹ 5,516.56 Cr |
Industry Peers & Returns | 1W | 1M | 1Y |
JUBILANT PHARMOVA | 5.1% | -10% | -53% |
SUN PHARMACEUTICAL INDUSTRIES | 1.6% | -2.6% | 23.2% |
DIVIS LABORATORIES | -2.2% | -0.2% | -14.5% |
DR REDDYS LABORATORIES | 1.6% | -0.1% | -17.5% |
CIPLA | 1.4% | -4.9% | -1.2% |
GLAND PHARMA | 1.7% | -7.3% | -17.1% |
PIRAMAL ENTERPRISES | 2.1% | -12.2% | -30.3% |
CADILA HEALTHCARE | 2.9% | -5.9% | -42.7% |
TORRENT PHARMACEUTICALS | -0.5% | -0.3% | -0.1% |
FUNDAMENTAL ANALYSIS OF JUBILANT PHARMOVA
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF JUBILANT PHARMOVA
 Ratio | Consolidated | |
---|---|---|
P/E P/B P/S |
6.59
P/E Calculated based on EPS of 52.51
[ Mar2021 - Consolidated Results ] 1.16
P/B Calculated based on Book Value of 297.84
[ Mar2021 - Consolidated Results ] 0.9
P/S Calculated based on Revenues of 6130.16 Cr
[ TTM - Consolidated Results ] |
|
Financial Ratios → |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
-58% -42% -39% |
SHARE PRICE MOMENTUM OF JUBILANT PHARMOVA
JUBILANT PHARMOVA vs SENSEX
DEBT OF JUBILANT PHARMOVA
Year | Debt/Equity ratio | |
---|---|---|
Standalone | Consolidated | |
2021 2020 2019 Avg_3yrs |
0.38 0.75 0.73 0.62 |
0.55 0.83 1.01 0.8 |
[Last Annual Data : Mar2021]
|
||
Financial Ratios → |
PLEDGED PROMOTER SHARES OF JUBILANT PHARMOVA
Pledged Promoter Shares |
NA | |
---|---|---|
If less than 25% | Good |
|
If between 25% and 50% | Neutral | |
If greater than 50% | Bad | |
Shareholding Pattern → |
QTRLY RESULTS OF JUBILANT PHARMOVA
Consolidated | Q-o-Q | Y-o-Y |
---|---|---|
Revenue Op Profit Profit Before Tax Profit After Tax |
16.56% 27.34% 48.62% 13.75% |
-3.31% -33.97% -56.78% -63.53% |
QtrlyTrend |
0 | |
Latest Qtr: Mar2022 | ||
Quarterly Result Analysis → |
JUBILANT PHARMOVA related INDICES
BSE Indices | 1W | 1M | 1Y |
---|---|---|---|
S&P BSE SMALL CAP | 4.5% | -4.9% | 0.1% |
S&P BSE 250 SMALLCAP | 4.1% | -5.3% | -3.1% |
S&P BSE MIDSMALLCAP | 3.9% | -4.9% | -0.9% |
S&P BSE 400 MIDSMALLCAP | 3.9% | -5.2% | -0.8% |
S&P BSE ALLCAP | 3% | -5.2% | -0.1% |
NSE Indices | 1W | 1M | 1Y |
---|---|---|---|
NIFTY SMALLCAP250 | 3.9% | -5.5% | -2.6% |
NIFTY MID SMALL400 | 3.8% | -5% | -0.5% |
NIFTY500 MULTICAP 50:25:25 | 3.2% | -5.2% | -0.5% |
NIFTY 500 | 2.8% | -5.2% | -0.4% |
You may also like the below Video Courses
FAQ about JUBILANT PHARMOVA
Is JUBILANT PHARMOVA good for long term investment?
As on Jun 29,2022, the Fundamentals of JUBILANT PHARMOVA look Strong and hence it may be good for long term investment! See Financial Performance of JUBILANT PHARMOVA . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is JUBILANT PHARMOVA UnderValued or OverValued?
As on Jun 29,2022, JUBILANT PHARMOVA is Under Valued based on the estimates of intrinsic value and hence may be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of JUBILANT PHARMOVA ?
As on Jun 29,2022, the Intrinsic Value of JUBILANT PHARMOVA is Rs. 594.58 determined based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 824.61
Fair Value [Median EV / Sales Model] : Rs. 594.58
Fair Value [Median Price / Sales Model] : Rs. 566.64
Median Fair Value of JUBILANT PHARMOVA : Rs. 594.58
Is JUBILANT PHARMOVA trading at a Premium or Discount?
As on Jun 29,2022, JUBILANT PHARMOVA is trading at a Discount of -42% based on the estimates of Median Intrinsic Value!SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs DR REDDYS LABORATORIES LTD
CIPLA LTD vs GLAND PHARMA LTD vs PIRAMAL ENTERPRISES LTD
CADILA HEALTHCARE LTD vs TORRENT PHARMACEUTICALS LTD vs ALKEM LABORATORIES LTD
LUPIN LTD vs AUROBINDO PHARMA LTD vs BIOCON LTD
ABBOTT INDIA LTD vs LAURUS LABS LTD vs IPCA LABORATORIES LTD
